Core Viewpoint - In the post-COVID era, CanSino's performance is showing signs of recovery, primarily driven by the sales of its meningococcal vaccines, despite the overall market challenges for meningitis vaccines in China [3][4]. Financial Performance - CanSino reported a revenue of 846 million yuan for 2024, marking a year-on-year increase of 137.01% [3]. - The company achieved a net loss attributable to shareholders of 379 million yuan, which is a 74.45% reduction in losses compared to the previous year [3]. - The adjusted net loss was 441 million yuan, reflecting a 72.61% decrease in losses year-on-year [3]. Vaccine Sales and Market Position - The two meningococcal vaccines generated approximately 794 million yuan in sales, representing a year-on-year growth of 41.31% [3]. - CanSino's four-valent meningococcal vaccine, "Manhaixin," is the first in China and the third globally approved for infants under six months, filling a significant market gap [4]. - Despite having a leading position in the four-valent meningococcal vaccine market, CanSino's overall market share remains low compared to other vaccines [4]. Market Dynamics - The demand for meningitis vaccines is influenced by the low incidence rate of the disease in China, which is approximately 0.2 cases per 100,000 people, with around 100 cases reported annually [5]. - The popularity of free Class I vaccines, which are more accessible to economically disadvantaged families, poses a challenge for the uptake of CanSino's vaccines [4][5]. Expansion Strategies - CanSino plans to expand the age range for its four-valent meningococcal vaccine to include children up to six years old and is preparing for clinical trials for ages 7 to 59 [6]. - The company is targeting international markets, particularly in Southeast Asia, the Middle East, North Africa, and South America, with successful registration in Indonesia and obtaining Halal certification [6][7]. - CanSino's strategy includes forming local partnerships to facilitate product registration and market promotion in foreign countries [7]. Future Prospects - CanSino is also close to launching its 13-valent pneumococcal conjugate vaccine (PCV13i), which has a broader market potential compared to meningococcal vaccines [7].